No products in the cart.
Pre-made Tifalibep benchmark antibody (trivalent bispecific, anti-ALB;FCGRT therapeutic antibody, Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;FCRN/FcgammaRn/alpha-chain Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-1022
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Tifalibep benchmark antibody (trivalent bispecific, anti-ALB;FCGRT therapeutic antibody, Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;FCRN/FcgammaRn/alpha-chain Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Tifalibep Biosimilar, Bispecific, Anti-Alb;Fcgrt Antibody: Anti-FDAHT/HSA/PRO0883/PRO0903/PRO1341;FCRN/FcgammaRn/alpha-chain therapeutic antibody |
|---|---|
| INN Name | tifalibep |
| Target | ALB |
| Format | trivalent bispecific |
| Derivation | NA |
| Species Reactivity | NA |
| CH1 Isotype | NA |
| VD LC | NA |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | Affibody |
| Previous Name | NA |
| Gm Offical Target Name | ALB,FCGRT |
| Package |
Previous
Next
